Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) is -22.46% lower on its value in year-to-date trading and has touched a low of $143.52 and a high of $218.88 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ALNY stock was last observed hovering at around $146.65 in the last trading session, with the day’s gains setting it 1.77%.
Currently trading at $148.42, the stock is -3.21% and -13.47% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.85 million and changing 1.21% at the moment leaves the stock -17.46% off its SMA200. ALNY registered -18.75% loss for a year compared to 6-month loss of -27.15%. The firm has a 50-day simple moving average (SMA 50) of $9.61 and a 200-day simple moving average (SMA200) of -$81.58.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -12.35% gain in the last 1 month and extending the period to 3 months gives it a -13.16%, and is -0.83% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.28% over the week and 3.38% over the month.
Alnylam Pharmaceuticals Inc (ALNY) has around 2100 employees, a market worth around $18.69B and $1.83B in sales. Profit margin for the company is -24.08%. Distance from 52-week low is 3.41% and -32.19% from its 52-week high. The company has generated returns on investments over the last 12 months (-18.61%).
Alnylam Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$1.18 with sales reaching $426.51M over the same period.The EPS is expected to shrink by -13.10% this year, but quarterly earnings will post 1.00% year-over-year. Quarterly sales are estimated to grow 33.60% in year-over-year returns.
788 institutions hold shares in Alnylam Pharmaceuticals Inc (ALNY), with institutional investors hold 95.60% of the company’s shares. The shares outstanding are 125.79M, and float is at 125.27M with Short Float at 2.42%. Institutions hold 95.22% of the Float.
The top institutional shareholder in the company is Capital World Investors with over 16.5 million shares valued at $3.13 billion. The investor’s holdings represent 13.20% of the ALNY Shares outstanding. As of Jun 29, 2023, the second largest holder is FMR, LLC with 12.49 million shares valued at $2.37 billion to account for 9.99% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 11.63 million shares representing 9.30% and valued at over $2.21 billion, while Baillie Gifford and Company holds 6.71% of the shares totaling 8.39 million with a market value of $1.59 billion.
Alnylam Pharmaceuticals Inc (ALNY) Insider Activity
The most recent transaction is an insider sale by SHARP PHILLIP A, the company’s Director. SEC filings show that SHARP PHILLIP A sold 30,000 shares of the company’s common stock on Feb 29 ’24 at a price of $151.34 per share for a total of $4.54 million. Following the sale, the insider now owns 0.0 shares.
Alnylam Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 28 ’24 that Greenstreet Yvonne (Chief Executive Officer) sold a total of 2,932 shares of the company’s common stock. The trade occurred on Feb 28 ’24 and was made at $155.31 per share for $0.46 million. Following the transaction, the insider now directly holds 48128.0 shares of the ALNY stock.
Still, SEC filings show that on Feb 28 ’24, Garg Pushkal (CMO & EVP Dev & Med Affairs) disposed off 574 shares at an average price of $155.30 for $89145.0. The insider now directly holds 8,666 shares of Alnylam Pharmaceuticals Inc (ALNY).
